Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

NCT01673282 · clinicaltrials.gov ↗

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Epilepsy With and Without Secondary Generalization

Interventions

DRUG: Lacosamide

Sponsor

UCB Pharma GmbH